Front. Neurol. Frontiers in Neurology Front. Neurol. 1664-2295 Frontiers Media S.A. 10.3389/fneur.2023.1245622 Neurology Correction Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles Fong Chloe C. † Spencer Julian † Howlett-Prieto Quentin Feng Xuan * Reder Anthony T. * Department of Neurology, University of Chicago Medicine, Chicago, IL, United States

Edited and reviewed by: Francesco Patti, University of Catania, Italy

 *Correspondence: Xuan Feng xfeng@neurology.bsd.uchicago.edu Anthony T. Reder areder@neurology.bsd.uchicago.edu

†These authors have contributed equally to this work and share first authorship

 08 08 2023 2023 14 1245622 23 06 2023 27 06 2023 Copyright © 2023 Fong, Spencer, Howlett-Prieto, Feng and Reder. 2023 Fong, Spencer, Howlett-Prieto, Feng and Reder

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles by Fong, C. C., Spencer, J., Howlett-Prieto, Q., Feng, X., and Reder, A. T. (2023). Front. Neurol. 14:1158487. doi: 10.3389/fneur.2023.1158487 anti-CD20 therapy B cell multiple sclerosis ocrelizumab T cell TLR section-at-acceptance Multiple Sclerosis and Neuroimmunology

In the published article, there was an error. The level of CD79B RNA at 2 weeks was typed incorrectly in the text.

A correction has been made to Results, “Expression of B-cell-related genes relevant to MS is downregulated after ocrelizumab infusion,” paragraph 1. This sentence previously stated:

“Genes included CD79A (fold-change at 2 weeks vs. time 0 = −272; at 6 months vs. time 0 = −172; not shown in figure because of extreme scale of change) and CD79B (−2.47; and – 2.46) (Figure 4A).”

The corrected sentence appears below:

“Genes included CD79A (fold-change at 2 weeks vs. time 0 = −272; at 6 months vs. time 0 = −172; not shown in figure because of extreme scale of change) and CD79B (−55.0; and – 2.46) (Figure 4A).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.